论文部分内容阅读
应用以吡喃阿霉素（THP）为主的PVTL联合方案治疗儿童急淋白血病（ALL）4例（3例初治诱导，1例复治诱导）；恶性淋巴瘤（NHL）晚期4例（1例复治诱导，3例定期强化治疗）。结果除1例ALL死于感染，余7例均获诱导缓解或继续缓解，目前仍接受系统持续化疗中。PVTL疗前2例NHL阿霉素累积剂量分别已达188mg／m2和260mg／m2。1例已有心电图示心肌损害，1例曾应用表阿霉素后发生一过性心慌、胸闷及心电图示心肌损伤电流，改用THP后均无心脏毒性损害。
Four patients with acute lymphoblastic leukemia (ALL) were treated with pyoproxadin (THP) -based PVTL (4 cases were induced by initial treatment and 1 case was treated by retreatment), 4 cases with advanced lymphoma (NHL) 1 induced retreatment, 3 cases of regular intensive treatment). Results In addition to 1 case of ALL died of infection, the remaining 7 cases were induced or continued to ease the response, the system is still under continuous chemotherapy. Two cumulative doses of NHL doxorubicin before PVTL treatment reached 188mg / m2 and 260mg / m2, respectively. One patient had electrocardiogram (ECG) myocardial damage, and one patient had transient palpitation, chest tightness and electrocardiogram after applying epirubicin Myocardial injury current, switch to THP after no cardiotoxic damage.